(Q36689814)

15 August 2017

1 reference

title

Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade (English)

1 reference

15 August 2017

1 reference

4

Daniele Cusi

1 reference

15 August 2017

Lucia Del Vecchio

1

1 reference

15 August 2017

Mirella Procaccio

series ordinal

2

1 reference

15 August 2017

Sara Viganò

series ordinal

3

1 reference

15 August 2017

publication date

1 January 2007

1 reference

Nature Clinical Practice Nephrology

15 August 2017

published in

1 reference

15 August 2017

volume

3

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

42-49

1 reference

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

Aldosterone-induced inflammation in the rat heart : role of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Secretion of a salt-retaining hormone by the mammalian adrenal cortex

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Do human vascular endothelial cells produce aldosterone?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

The aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Role of aldosterone in the remnant kidney model in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Regression of existing glomerulosclerosis by inhibition of aldosterone

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Aldosterone: a mediator of myocardial necrosis and renal arteriopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Effect of aldosterone on renal transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

CLINICAL CHARACTERISTICS OF PRIMARY ALDOSTERONISM FROM AN ANALYSIS OF 145 CASES.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Relative glomerular hyperfiltration in primary aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Long-term renal outcomes in patients with primary aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Beneficial impact of spironolactone in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0362

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0362

1 reference

15 August 2017

1 reference